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This thesis is made for an Austrian company, RIVIERA Pharma & Cosmetics GmbH. 
The company produces traditional cosmetics, food supplements and traditional herbal 
medicines among other products. The company is launching an export process to Finland. 
This thesis is a compilation of European Union regulations and Finnish regulations which 
affect the process and an assemblage of necessary steps regarding the process.  
 
The thesis is constructed to provide specific information regarding certain product groups 
that are subject to the export process. The five product groups that are taken into 
consideration are dangerous goods, cosmetics, medical devices, food supplements and 
traditional herbal medicines. The focus is on information that needs to be provided, 
translations and notifications to be provided for the competent authorities.  
 
The export process requires relatively little actions because of the harmonized legislation 
inside EU. The product information needs to be translated partly or completely to Finnish 
and Swedish with every product group. That includes instructions for use, ingredients and 
possible cautions. The fact, that it is probably not worthwhile to include the traditional 
herbal medicines in the export process, is discussed. The person who is setting the 
products on the market is responsible for the notifications made to the competent 
authorities and the conformity of the translated information. Co-operation is required 
between the producer and the distributor as well as the distributor and the competent 
authority. The role of interpretation of the regulations is discussed.  
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Tämä opinnäytetyö on tehty itävaltalaiselle yritykselle RIVIERA Pharma & Cosmetics 
GmbH. Yritys valmistaa monia tuotteita, kuten perinteistä kosmetiikkaa, ravintolisiä ja 
perinteisiä lääkerohdoksia. Yrityksen tavoitteena on saattaa tuotteitaan Suomen 
markkinoille ja se on aloittanut vientiprosessin. Tämän opinnäytetyön tarkoituksena on 
koota olennaiset seikat Euroopan Unionin lainsäädännöstä sekä kansallisesta 
lainsäädännöstä liittyen vientiprosessiin ja sen vaiheisiin. 
 
Opinnäytetyö keskittyy tarkastelemaan tiettyjä tuoteryhmiä, jotka ovat mukana 
vientiprosessissa. Nämä tuoteryhmät ovat vaaralliseksi luokitellut aineet, kosmetiikka, 
terveydenhuollon laitteet, ravintolisät sekä perinteiset kasvirohdosvalmisteet. Erityisesti 
työssä keskitytään kuvaamaan kaikki tiedot, jotka täytyy kääntää, kenelle tiedot tarvitsee 
toimittaa sekä toimivaltaisille viranomaisille tehtävät ilmoitukset.   
 
Vientiprosessi vaatii suhteellisen vähän toimia Euroopan Unionin yhdenmukaistetun 
lainsäädännön ansiosta. Kaikki tuotetiedot on käännettävä suomeksi ja ruotsiksi joko 
kokonaan tai osin. Niihin kuuluu käyttöohjeet, sisältö ja mahdolliset varoitukset. Työssä 
todetaan myös, että perinteisten lääkerohdosten vienti Suomeen ei ole todennäköisesti 
järkevää. Tuotteet Suomen markkinoille asettava taho on vastuussa toimivaltaisille 
viranomaisille tehtävistä ilmoituksista, sekä tarkistamaan tuotteiden 
vaatimustenmukaisuuden. Yhteistyötä edellytetään valmistajan ja maahantuojan välillä 
sekä maahantuojan ja toimivaltaisen viranomaisen välillä. Työssä tarkastellaan myös 
lakien tulkinnanvaraisuutta.  
 
Asiasanat: vienti, EU:n sisämarkkinat, ravintolisät, kosmetiikka, perinteinen 
kasvirohdosvalmiste, vaaralliseksi luokitellut aineet 
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ABBREVIATIONS AND TERMS 
 
 
ADR European Agreement concerning the Carriage of Dangerous 
Goods by Road 
AGES Austrian Agency for Health and Safety Ltd. 
Annex Annex is an attachment of a European Union Regulation or 
Directive. The related legislation is always stated in the 
connection of the discussed annex.  
CE Conformité Européenne (CE-marking) 
CLP (EC) No 1272/2008 Classification, Labelling and Packaging 
of substances and mixtures 
CMDh Co-ordination Group for Mutual Recognition and 
Decentralized Procedures - Human 
CPNP Cosmetic Product Notification Portal 
EC European Community 
ECHA European Chemicals Agency 
EDQM European Directorate for the Quality of Medicines 
EEC European Economic Community 
EMA European Medicines Agency 
EU European Union 
Eudamed European Database on Medical Devices 
Evira Finnish Food Safety Authority 
(Elintarviketurvallisuusvirasto) 
Fimea Finnish Medicines Agency (Lääkealan turvallisuus- ja 
kehittämiskeskus) 
FPVO Fertigpackungsverordnung 1993  
GMP Good Manufacturing Practice 
IDV -product In Vitro Diagnostics product 
INCI International Nomenclature of Cosmetic Ingredients 
ISO International Organization of Standardization 
MRP Mutual Recognition Process (Registration of pharmaceutical 
products) 
REACH (EC) No 1907/2006 Registration, Evaluation, Authorization 
and Restriction of Chemicals 
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SPC The summary of the product characteristics  
SRN -number Single Registration Number (Eudamed) 
Tukes Finnish Safety and Chemicals Agency (Turvallisuus- ja 
kemikaalivirasto) 
VAT Value Added Tax 
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1 INTRODUCTION 
 
 
This Bachelor’s Thesis is made for company called RIVIERA Pharma & Cosmetics 
GmbH. It is an Austrian family-owned company with a long tradition. The company was 
founded 1923 and it produces traditional herbal medicinal products as well as creams, 
oils and ointments. (RIVIERA, 2014) 
 
The company is seeking to enter the Finnish market. I have worked for the company for 
four months, conducting a research on different possibilities and contacting possible 
partners in Finland. For a successful market entry, the basic knowledge of regulations 
about the products is crucial. This thesis work is an assemblage of regulations in the 
European Union as well as national regulations in Finland regarding the different product 
groups of the company. Its purpose is assisting the exporting process by explaining all 
the necessary steps regarding the regulations in the exporting process.  
 
The exporting process is relatively easy because of the unified systems of the EU. 
Nevertheless, local practices vary from place to another and it is necessary to know the 
responsibilities of each operator in the process. A recapitulation of the local authorities 
and procedures makes the whole process more effective. Furthermore, all necessary 
information gathered in this thesis can expedite the export process of the company. The 
goal of this work is creating an easily accessible manual regarding exporting to Finland.  
 
This thesis covers pharmaceutical products, medical devices, cosmetics, food 
supplements and sauna infusion oils, which are classified as dangerous goods because of 
their high alcohol content. The company produces also animal care products but they are 
not included in this thesis work. For all of the mentioned product groups, there are 
divergent national regulations and for some also special authorization procedures. This 
thesis is written for the specific products or product groups but the general information 
can be implemented for other products in relatable product groups as well. 
 
In this thesis, exporting is used to describe the process of selling Austrian products in 
Finland. In the EU, the member states have a right to import and export products freely 
and the governments of the countries are not allowed to restrict the trade in any way. The 
EU also enables the transport of goods freely in the internal market. Sometimes there are 
8 
 
restrictions based on national rules. Then the government must demonstrate that such 
restrictions are a true risk to the life of humans, animals or plants as well as environment, 
public security or public moral. (Your Europe, 2017.) As an example, Finland has a lot 
stricter alcohol regulations compared to many other European countries.  
 
Exporting within the EU is considered as an intra-Community transaction (Trade 
Helpdesk). However, the basic process of exporting can be implemented to the intra-
Community transaction. The advantage of intra-Community transaction in comparison to 
exporting from outside the EU is the European wide unified systems and regulations as 
well as the free movement of goods. Furthermore, the value-added tax, VAT, is only to 
be paid to the member country in which the products are sold. The local VAT in Finland 
is 24%; that applies to all other products except food supplements whose VAT is 14 % 
and medicines whose VAT is only 10%. (Trade Helpdesk.) 
 
Exporting consists of several phases and it begins either with an external offer or request 
or the company’s will or need to expand. The next phase is making an analysis of foreign 
markets and the possibilities there and a study of the requirements to reach those markets. 
The products that fit the new markets are chosen and deeper analysis about the target 
groups and local requirements and legislation is applied. It is crucial to find suitable ways 
to operate on foreign markets and when necessary, co-operating with local partners. Sales 
promotion and marketing are significant parts of foreign trade.  
 
Formulating all the contracts, minding suitable insurance and transportation and 
packaging, as well as calculating suitable prices are de rigueur for the export process. 
Budgeting and documentation are also very important parts of the operation. Furthermore, 
the company must be able to finance the whole process. Normally export costs rise above 
the gained profit in the beginning of the process. (Yrittäjät. n.d.) Maintaining good export 
rates requires alertness with the market development, changing legislation and new trends 
as well as following the satisfaction of the customers (Vientiprosessiopas, 2013.) The 
basic export process is explained in figure 1. 
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FIGURE 1. Export Process  
 
To ease the export process, a table describing the responsibilities of RIVIERA Pharma & 
Cosmetics GmbH and the Finnish distributor regarding each product category has been 
compiled. That table is presented in German in appendix 1 and in English in appendix 2. 
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6. Shipping (packaging, documentation etc.)
7. Afterwork (maintaining steady sales and 
following the development of the markets 
and satisfaction of the customers)
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2 DANGEROUS GOODS 
 
 
The most important laws regarding the chemical industry in Europe are No. 1907/2006 
REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) and No. 
1272/2008 CLP (Classification, Labelling and Packaging of substances and mixtures). 
These laws bind all the member states. The purpose of the laws is to ensure high quality 
in health and environmental protection, enhance the competitiveness of chemical industry 
in the EU and assure the free transport of goods within the Community. (Tukes, 2016.) 
 
The only products of RIVIERA that are considered dangerous goods are the sauna 
infusion oils. The high alcohol content of the products makes them easily flammable. All 
other product groups fall under their own legislation. Appendix 3 contains a statement 
from the company regarding the products that fall under the CLP legislation. However, 
some cosmetic products and dietary supplements have also high alcohol which makes 
them belong under the same law as the sauna infusion oils regarding transportation. 
(Tukes, 2017.) 
 
 
2.1 REACH 
 
REACH gives the guidelines for chemical registration, evaluation and authorization of 
the chemical. It also states the borderlines for dangerous chemicals and regulates the 
restrictions. It is valid from 01.07.2007. In principle, the REACH-regulation can be 
implemented in all chemical substances and not only in those which are used in industrial 
processes. This includes substances that are present in everyday life, such as detergents 
and paints as well as substances that are present, for example, in clothing, furniture and 
electrical devices. The vast area of implementation makes the regulation relevant for most 
of the companies in the European Union. (ECHA. n.d.) 
 
The regulation shifts most of the responsibility to the companies. The companies are 
obliged to prove to the European Chemical Agency (ECHA) that chemicals can be used 
safely, give instructions on their use and inform the users about risk management 
procedures. If the risks are not manageable, authorities can restrict the use of the 
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chemicals in various ways. In the long term, the most dangerous chemicals must be 
substituted with less dangerous ones. (ECHA. n.d.) 
 
The REACH draws the necessary guidelines for gathering and evaluating information 
about the dangers and properties related to the substances and chemicals. Registering all 
substances is a responsibility that every company holds. When a company imports or 
produces a chemical more than a ton a year, the chemical or substance needs to be 
registered. Collaboration with other companies that are registering the same substances 
is also required. (ECHA. n.d.) 
 
ECHA receives singular registrations and evaluates their compliance with regulations. 
The member states evaluate certain substances regarding the local conditions as well as 
possible threats to human health or environment. Authorities and ECHAs scientific 
committees evaluate whether the risk management is appropriate. Authorities can forbid 
dangerous substances when the risks cannot be controlled. They can also decide on 
restrictions of usage or state if the use of the chemicals is subject to licence. (ECHA. n.d.) 
 
The regulation has a great effect on many companies, even those who do not consider that 
they work with chemicals. The REACH regulation determines different roles for 
operating parties. Producer is the party who produces chemicals either for their own use 
or for the use of other parties. Producer has to make sure its operations are applicable with 
the REACH regulation. Producer makes the registration of product to ECHA which 
includes providing a package of technical information on the chemical and its hazards. 
(Komptmann, S. 2014.) 
 
The Law itself describes all of the processes from registration and evaluation to 
authorisation. It aims to unify the systems regarding chemicals within the European 
Economic Community. It states all the necessary actions of each operator in a supply 
chain. According to the article 5 of 1907/2006, without registration a chemical shall not 
be placed on the market.  
 
The registration is not a concern because the products are already registered and have 
been on the market for decades. Article 31 describes the requirements for safety data 
sheets, the details are explained in annex II. Article 31 (5) states that the safety data sheets 
need to be given by the official languages of the member state in which the products 
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concerned are to be placed on the market. (1907/2006.) However, the national chemical 
law 599/2013 in Finland states that safety data sheets need the be either in Finnish or in 
Swedish. Therefore, safety data sheets of the certain scents of sauna infusion oils which 
are to be placed on the market need to be translated only into Finnish. 
 
The safety data sheets need to be delivered to the distributor at the latest the same day the 
products arrive (1907/2006). The competent authority for chemicals in Finland is Tukes. 
(599/2013). When a chemical is brought to a local market a notification is to be made to 
the competent authority by the person who brings the product to the market. In this 
instance, the distributor shall make the notification. According to the national law 
1155/2011 of the notification, the third article states that the notification is always to be 
made before the end of the following year’s February.  After the notification, information 
is only to be provided in case of change (1155/2011).  
 
The information that needs to be provided for the notification follows the framework of 
safety data sheets. In addition, the distributor is responsible of giving additional 
information about the products upon request whereas the manufacturer is responsible for 
providing that information to the distributor. (Tukes, 2016.) Both the manufacturer and 
the distributor are liable to hold on to the information regarding the safety of the chemicals 
at least for 10 years after the end of the use of the chemical. Furthermore, the manufacturer 
is liable to inform the distributor about changes regarding the safety of the chemical or 
changes in the safety data sheets. (1907/2006.) 
 
 
2.2 CLP 
 
As the name indicates, the European Community regulation 1272/2008 describes the 
classification, labelling and packaging of substances and mixtures. It is applicable in the 
whole are of European Community. The regulation states the guidelines for the 
classification of the substances and mixtures. Many of the chemicals are classified as 
hazardous. Thus, the number of obligations related to handling, labelling, packaging and 
transport increases. (1272/2008.) The sauna infusion oils are classified as hazardous. The 
products have already been on the market for decades, hence the general obligations 
related to the regulation have been updated as the laws have changed. The CLP regulation 
also demands the observance of the REACH regulation in article 4 (1272/2008). 
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The requirements of CLP are also written down in the national chemical law of Finland 
599/2013. The most crucial part of the CLP-regulation in this connection is labelling. 
Article 17 states all the information that needs to be given in a label, as well as that the 
information needs to be given in the official languages of the member state. The 
information required according to article 17 is shown in the table 1.  
 
TABLE 1. Labelling requirements according to article 17 of regulation (EC) No 
1272/2008 
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Annex I point 1.2 states the labelling instructions. The information about the signal words 
is also stated in annex I. The pictograms are unified, but all the signal words, hazard 
statements and additional information need to be easily readable in the label of the 
container and outer packaging in the official language of the member state. Annex II gives 
more detailed description about the elements and contents of the label. There is a demand 
in point 3.2 to use tactile warning of danger in certain situations. In this instance, the 
demand is applicable. Therefore, the products have tactile warnings made according to 
EN ISO- 11683. (1272/2008.) 
 
The label can contain more than one language. All the information provided in the form 
of hazard statements, hazard pictograms, signal words or precautionary statements needs 
to be the same in every language. This information also needs to be located together in 
the label according to article 32. However, the information needs to be grouped by 
language in order to keep the label easily readable and as informative and clear as 
possible. (1272/2008.) 
 
In conclusion, the content of the labels regarding signal words, precautionary statements 
and hazard statements needs to be translated to both Finnish and Swedish and the 
pictograms also need to be included. Furthermore, the REACH-regulation requires 
providing instructions for use in the languages of the member states which means that the 
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instructions also need to be provided in both languages. In addition, the safety data sheets 
need to be provided in either language or both (599/2013). 
 
 
2.3 ADR 
 
Directive 2008/68/EC on the inland transport of dangerous goods determines the general 
procedures and rules regarding the transportation of dangerous goods within member 
states. Both Austria and Finland have agreed to the terms of the directive. ADR covers 
the international carriage of dangerous goods by road. (2008/68/EC.) 
 
The agreement includes the responsibilities of different operating parties, also during the 
actual transportation. Only persons who have an ADR driving licence are qualified to 
transport dangerous goods. (Trafi, 2017.) The national law of transportation of dangerous 
goods in Finland is set in 719/1994 and transportation of dangerous goods by road in 
194/2002. The national competent authority ensuring the fulfilment of the requirements 
for transportation of dangerous goods is Tukes. (Tukes, 2017.) The agreement eases the 
transportation process, as the requirements are similar. 
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3 COSMETICS 
 
 
Cosmetics are products that are intended to be applied directly on the external parts of 
human body as well as teeth and mucous membranes of the oral cavity. The external parts 
of human body include skin, hair, nails, lips and external genital organs. The aims of the 
cosmetic products can be cleaning, perfuming, changing appearance, protection, 
maintaining good condition or correcting body odours. (1223/2009.) 
 
Regarding cosmetics, the situation is easy because there is a collective law in the whole 
area of the European Community that is directly applicable in all of the member states. 
The (EC) No 1223/2009 on cosmetic products summarises the requirements on cosmetic 
products including the guidelines for manufacturing, distribution, safety, free movement 
within the EU as well as several other crucial matters such as the responsibilities of 
different operators handling the products and prohibition of animal testing. (1223/2009.) 
 
One of the most important matters with cosmetics are the ingredients. With the Cosmetic 
legislation, the International Nomenclature of Cosmetic Ingredients (INCI) was taken into 
use in the whole area of the European Community. The aim of the INCI is to harmonize 
the system of labelling cosmetic products. It compiles the most common ingredient 
names. The harmonization of the names of the ingredients helps the end users to recognise 
the ingredients in the whole European Community and therefore, for example, exclude 
the products that are not suitable for oneself. Furthermore, no translation is needed for the 
ingredients. The INCI is enacted in the 33rd article of 1223/2009.  
 
Furthermore, The INCI-list indicates also the amounts of different ingredients in the 
product. The ingredients need to be stated in an order from the biggest m-% to the 
smallest. With the ingredients whose content is less than 1 % the ingredients can be stated 
in any order. Some aromatic compounds that can cause contact allergy are stated 
separately when the content has exceeded a certain amount. (Teknokemian yhdistys ry. 
n.d.) 
 
The fact that the products are all produced and transported within the EU ensures that the 
initial requirements regarding the law are fulfilled to begin with. The law determines 
clearly the ingredients that can in certain amounts or cannot be used. It also states in 
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article 8, that all of the products are required to be produced according to the GMP, a 
good manufacturing practice. The Cosmetic GMP is described in the standard ISO 22716. 
It sets high requirements to ensure consumer safety. It concerns all participants in the 
cosmetics product chain and sets guidelines for different factors that can affect the quality 
of the product. (Bureau Veritas Group. n.d.) Nevertheless, the company produces also 
products that are classified as pharmaceutical products and therefore the company follows 
the guidelines of Pharmaceutical GMP that are even stricter and require better quality 
control. Hence, the requirements of Cosmetic GMP are automatically fulfilled. 
 
Moreover, there is a national law in Finland that states the local authorities and their roles, 
the monitoring of the safety of the products as well as the local language requirements. 
The local responsible competent authority named by the Ministry of Social Affairs and 
Health is Tukes, the Safety and Chemical Agency. They are also the authority to be 
immediately informed in case of serious symptoms caused by the product. Finnish 
Customs is also stated as the competent authority in some situations. For example, they 
can conduct spot checks on the cosmetic products that are entering the Finnish market. 
(492/2013) 
 
According to the article 11 of 1223/2009 the product information file that includes all the 
necessary information about the products, such as the safety assessment, method of the 
manufacturing and general information about the product, needs to be available to the 
competent authorities of the member state. The Finnish cosmetic law 492/2013 states that 
in addition to Finnish and Swedish, English is a sufficient language for the product 
information file.  
 
When a new product is placed in the market, a notification is needed to be made according 
to the article 13 of 1223/2009. Since all of the products are already on the market, the 
initial notification is already made. Nevertheless, the distributor is required to make an 
additional notification and, by their own initiative, to translate the necessary information 
into languages required by the national law of the member state. This includes the 
category of the product, the name of the product in the member state of origin and the 
name in the member state in which the product is to be made available as well as the name 
of the member state itself, the name and address of the distributor and the name and 
address of the responsible person who is in this instance the producer. (1223/2009.) The 
notification is made in the CPNP portal (Cosmetic Product Notification Portal). 
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The 1223/2009 states that the translations of the quantity, preservability, instructions and 
cautions as well as the aimed use, if it is not obvious, are to be enacted in a national law. 
The cosmetic law 492/2013 states that the mentioned facts should be translated into both 
Finnish and Swedish. The amount of content is directly informed according to the 
Austrian national regulation Fertigpackungsverordnung 1993, which is also based in an 
EU directive, that states the quantities and how they should be entered in all kinds of 
packaging. The form is directly applicable in all EU countries. On the other hand, the 
1223/2009 gives the symbols to be used in packaging in annex VII. Those give the means 
to inform the “best before”-date as well as how long the product stays good after opening.  
Thus, the possible cautions, name and instructions are the only things left to be translated. 
(1223/2009.) The compliance certificate of the EU regulation of cosmetics is shown in 
the appendix 4. 
 
 
The transportation of liquid with alcohol content is stated in the EU ADR directive. ADR 
is explained in point 2.3 of this document. The requirements of the ADR need to be 
considered also with the cosmetic products that have high alcohol content. 
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4 MEDICAL DEVICES 
 
 
RIVIERA Pharma & Cosmetics will produce products in the future that fall into the 
product category of medical devices. The directive about the medical devices is 
93/42/EEC, which was replaced by the (EU) 2017/745 in April 2017 (Valvira, 2017). 
However, the specifications of the new regulation are to be adopted by 26 May 2020 
(2017/745). The previous law was enacted to national law of Finland in 629/2010. The 
EU directive is to be applied into the member states national laws as it is, similar to the 
cosmetic law. That makes the exporting of medical devices within the EU area very 
convenient, which naturally is one of the aims of a harmonized law system.  
 
A medical device is an instrument, apparatus, appliance, software, implant, reagent, 
material or other article that is used for diagnosis, prevention, treatment or alleviation of 
disease; control of conception; diagnosis, monitoring, treatment, alleviation of or 
compensation for an injury or handicap, or investigation replacement or modification of 
the anatomy or of a physiological process. There are also some other specifications. The 
main purpose of the product should not be received by pharmaceutical, immunological or 
metabolic means in or on the human body. Nevertheless, it may be assisted in its function 
by such means. (2017/745.) 
 
The manufacturer bears the main responsibility regarding the product. There are many 
requirements for the products such as appropriate quality and risk management, 
appropriate labelling and general safety of the product. General safety and performance 
requirements are stated in the annex I of the 2017/745. The medical device directive states 
that the member states are required to ensure that the products are completely safe. The 
annex I is very informative and gives e.g. in point three, all the necessary steps for risk 
management.  
 
The medical devices that fulfil the requirements stated in 2017/745 receive the CE 
marking. The marking is showed in figure 2. The figure shows the correct dimensions 
which are not to be altered even if the size of the mark was to be changed. The mark 
should be at least 5 mm in size. (Scholtz, S., Menzl, S., Rupparath, C., Becker, M. and 
Auffarth, G.). 
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The CE marking is an international indication that the manufacturer has ensured that the 
products comply with all necessary directives. In order to receive the CE marking, the 
requirements for declaration of conformity need to be fulfilled, that includes a clinical 
evaluation which is described in article 61. Additional information is provided in annexes 
XIV and XV. Annex IV of 2017/745 gives a list of information and requirements needed 
for the declaration of conformity. The procedures for the assessment of conformity are 
described in annexes IX – XI. When the product is to be set on market in other member 
states, the information regarding the declaration of conformity and possible additional 
information is to be given in the official languages of the member state. (2017/745.) 
Therefore, the information in question needs to be translated to both Finnish and Swedish 
unless the Finnish competent authority states otherwise.  For the moment, translation is 
obligatory.  
 
 
FIGURE 2. The CE –mark and its dimensions (Scholtz, S. etc.). 
 
Medical devices are classified in different classes depending on their intended use. Annex 
VII of 2017/745 states the classification criteria. The class of the product determines some 
of requirements for the product (2017/745). The classification needs to be considered 
when initiating the process of manufacturing. The competent authority in Finland is 
Valvira. A notification is to be made to Valvira for the export if the products are In vitro 
diagnostics (IDV) -devices meant for self-testing or products that include or that are made 
of substances that are made from human tissue, human blood or plasm, excluding IDV 
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devices meant for professional use. Hence, those requirements are not applicable for the 
products of RIVIERA Pharma & Cosmetics GmbH, a notification for the local authority 
is not necessary. (Valvira määräys 2010.) 
 
However, the system is about to change in to the direction where all necessary information 
and involved bodies are given through an electronic system, a European database for 
medical devices, Eudamed. In accordance to articles 29-31, the system gives a basis for 
the information related to medical devices that needs to be applied by different operators. 
It should also include the space for translations. As stated in article 33, it enables a unified 
nomenclature for medical devices. (2017/745.) 
 
The system provides a certain SRN number for each manufacturer. The number is also 
needed for the declaration of conformity. Eudamed also requires regular checks on the 
applicability of the provided information in the system. The Eudamed system is open for 
all member states and other involved bodies. Article 123 of 2017/745 states that the 
Eudamed system should be fully functional by 25 March 2020. Hence, for the time being, 
for those parts of 2017/745 that cannot be implemented, the old regulation 93/42/EEC 
stands. Article 123 lists the articles of 2017/745 that are immediately applicable. 
(2017/745.) 
 
There is a system of harmonized standards that is in operation at least in the area of the 
European Community. The article 8 of 2017/745 binds the manufacturers to use the 
harmonized standard system. The standards summarise the necessary methods for e.g. 
manufacturing, risk management and clinical evaluation. The manufacturer is responsible 
for picking up the requirements and standards that are relevant and how the fulfilment for 
those requirements is shown. (Salminen, L, 2013) For example, standard EN ISO 10993-
1:2009 describes the biological evaluation of medical devices (European Commission: 
Harmonized Standards. n.d.). Whereas ISO 13485 and ISO 9001 describe the quality 
management, IEC 62366 describes the suitability for use and EN ISO 17050 conformity 
assessment (Dr. Heinz, R & Partner, 2016). 
 
Point 23 of the annex I states all the information that needs to be provided about the 
product in all member states where the product is set on market.  The information shall 
be given in the languages the member state has dictated. (2017/745.) The national 
language law of Finland 6.6.2003/423 states in article 34, that all the products that are set 
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for sale need to have the product name, instructions, trade description and possible 
cautions translated to both Finnish and Swedish. Thus, all the information mentioned in 
the annex I of 2017/745, point 23, has to be translated into Finnish and Swedish. 
 
The new law is much more precise and defines the guidelines in great precision. For 
example, article 10 (9) outlines the quality management system the manufacturer needs 
to have. The manufacturer is also required to do post market surveillance regarding the 
medical devices it has placed on market. Annexes II and III state all the technical 
documentation required from the manufacturer, those include e.g. instructions regarding 
the risk management and post market surveillance. Article 15 obliges the manufacturer to 
have either in their own organization, or an available person who is responsible for the 
regulatory compliance, depending on the size of the company. The responsible person is 
responsible for e.g. conformity of the quality management system, post market 
surveillance and reporting according to articles 87 and 91. (2017/745.) 
 
Article 14 states the general obligations of distributors. Those include ensuring that the 
CE marking and declaration of conformity are appropriate, the information in the annex 
I, point 23 is accordingly provided in national languages, the storage and transport are 
dealt according to the instruction given by the manufacturer and inform the manufacturer 
when there are problems with the conformity or some complaints or risks regarding the 
products arise. The distributor is also obliged to give any necessary information to 
competent authority upon request. The manufacturer is required to keep record about 
complaints and possible health issues and when necessary, reassess the safety of the 
products. (2017/745.) 
 
The law includes so called “borderline products” which can be easily classified also as 
another product group. For example, some products might have some medicinal 
substances included so that they work with a physical basis but also include a substance 
that is classified as a medicine. National laws in different member states may have a 
different kind of focus, which leads to a situation that in some states a product is a medical 
device, but in another a medicine. (Salminen, L. 2013.) Due to the nature of the products 
RIVIERA will be producing, the national laws in Finland are not likely to cause any 
contradiction regarding the classification of the product. There are already similar types 
of products registered as medical devices on the local market. 
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The transition phase of the laws lays its own challenges for all involved bodies. 
Manufacturers need to follow the possible changes and updates continuously. 
Nevertheless, the only sensible option is to aim to fulfil the requirements of the new law 
since the beginning of the operation and update the operation simultaneously as the 
demands in the law are beginning to stand. 
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5 FOOD SUPPLEMENTS 
 
 
5.1 General information about food supplements 
 
As the dietary supplements fall under the legislation for foodstuffs, the amount of 
regulations and demands is enormous. However, the requirements and legislation have a 
base in the EU regulations drawing the framework for the operation. In appendix 5 is 
presented a declaration of conformity which states the accordance of certain legislation 
listed in the declaration.  
 
There is a European regulation 178/2002 regarding the safety and setting up the authority 
for safety of foodstuffs and the general safety procedures of foodstuffs. The requirements 
of the mentioned law need to be followed in all areas of operation regarding foodstuffs. 
The different European Union regulations about foodstuffs are enacted in the national 
Food Act 13.6.2006/23. (Ravintolisäopas, 5.) Furthermore, there is a regulation 78/2010 
of Ministry of Agriculture and Forestry about food supplements, which is based in the 
European Community directive 2002/46/EC.  
 
The competent authority in Finland regarding foodstuffs is Evira. The following 
information is a compilation of the food supplement guide by Evira and therefore follows 
their interpretation of the legislation. As stated in 78/2010, a food supplement is a pre-
packed product in the form of a capsule, briquette, pastille, tablet, pill, powder, 
concentrate, extract, liquid or some other product that is in dose form. The food 
supplements are consumed in small quantities and do not have a significant effect on the 
energy intake. The food supplements have physiological or nutritional effect as a 
concentrated from of the substance. As the name states, food supplements are supporting 
and supplementing a normal, healthy and balanced diet, not substituting it. 
(Ravintolisäopas, 6.) 
 
Evira requires a notification when a new food supplement is placed on the market. The 
notification is to be placed by the person who is responsible for setting the product on 
market. Therefore, in this instance, it is the distributor. The notification needs to be placed 
before or at the latest as the products are placed on the market. With the notification, Evira 
requires a model of labelling. Attachments can also be provided. However, Evira does 
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not evaluate the conformity of the product. The conformity rests upon the operator. The 
submitting of the notification includes a fee. In addition, the distributor needs to have 
suitable space, a food establishment, for storing, handling the products. (Ravintolisäopas, 
36.) 
 
The food supplement consists of a certain substance or a substance which gives the 
specific effects with some additional substances. In the European Community regulation 
1170/2009 is a list which includes vitamins and nutrients that are allowed to be used in 
food supplements. In the declaration of conformity in appendix 5, is stated that the food 
supplements of RIVIERA Pharma & Cosmetics are made in accordance of the regulation. 
There are also the specific purity demands regarding foodstuffs. The same document in 
appendix 5 states that the requirements for purity are followed. (Ravintolisäopas, 26.) 
 
 
5.2 Food supplements of RIVIERA Pharma & Cosmetics GmbH 
 
If the food supplements consist of animal based substances they fall under 853/2004 in 
addition to 23/2006 regulation. The 853/2004 states special hygiene requirements for 
animal based foodstuffs. When animal based products are imported to Finland from 
within the EU, a notification to Evira’s first arrival office is required to be made (Evira, 
2017). However, the product “Propolis juice”, which contains propolis that is made by 
bees and therefore is animal based, is classified as a compound of a processed animal 
based substance and a plant based substance and therefore the first arrival notification is 
not applicable (853/2004). 
 
With herbal extracts, there is a possibility of classification as medicine. The national 
medicine law 395/1987 states in article 3 (amended 4.11.2005/853) that in unclear 
situation where a product can meet the properties of a medicine when taken into 
consideration all of its properties, it is considered primarily a medicine, even if it would 
be considered as another type of product in some other legislation. Evira recommends 
consultation with the competent authority of Finland, Fimea, if the ingredients of the food 
supplement are found in the lists of medicinal substances and medicinal herbs. 
(Ravintolisäopas, 14.) 
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Nonetheless, the legislation on foodstuffs does not prevent using the substances that are 
mentioned in the lists of medical substances in a food supplement as long as the effect is 
not caused by the medical property of the substance. (Ravintolisäopas,14.) A Ribwort 
Plantain is the main ingredient in one of the food supplements made by RIVIERA. It is 
not found in the list of medicinal herbs; therefore, consultation is not needed (201/2016). 
 
However, a question may arise regarding the Schweden Bitter which is a food supplement 
produced by RIVIERA. It contains 13 different herbs some of which are included in the 
list of medicinal herbs. Yet, if it can be stated that the marketed effects are not caused by 
the medicinal properties, the sales as a food supplement should succeed.  
 
The alcohol content of the Schweden Bitter is also a property that makes it fall under 
alcohol legislation. According to the national alcohol law 8.12.1994/1143 the Schweden 
Bitter is an alcohol product. As a result, the taxation of alcohol products is needed to be 
taken into consideration in the pricing process. According to the national law 
29.12.1994/1471 of alcohol tax, the tax for this product is 45,55 €/cl/ethyl alcohol, as it 
is in the class 2208 of customs tariff and contains more than 2,8 % of alcohol. In this 
instance, the distributor in Finland is also required to have a permission for wholesales of 
alcohol granted by Valvira. However, the distributor does not need a separate permission 
for the sales of food supplements which contain alcohol.  
 
 
5.3 Requirements for labelling  
 
Regarding the labelling, the Food Act 23/2006 gives the initial requirements for labelling. 
The decree 834/2014 of the Ministry of Agriculture and Forestry on the provision of food 
information to consumers instructs to provide the labels as a whole in both Finnish and 
Swedish. In tables 2 and 3 are presented the requirements for labelling according to the 
Food Act 23/2006 and the Food Supplement act 78/2010. Figure 3 shows an example of 
the labelling.  
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TABLE 2. The requirements for labelling of foodstuffs according to Food Act 23/2006 
 
The name of the product • Gives a clear statement of the 
content of the food supplement  
• Only brand name is not sufficient  
• The names of medical products 
shall not be used 
The amount of content  
The operator who is responsible for the 
product and address 
The producer, in this instance, RIVIERA 
Ingredient list • The contents need to be listed in 
the order from the largest weight 
to the smallest.  
• Evira recommends using the 
names of plants in the national 
language where applicable.  
• Contents that cause allergies and 
intolerances need to be 
emphasized in the ingredient list 
• Additives need to be listed so that 
their purpose is also stated 
• The amount of emphasized 
ingredient needs to be stated 
Best Before- marking “Best before the end of XX/XXXX” 
Origin of the product Already stated through the producer 
Instructions for use • Clear description for use 
• Possible limitations and 
restrictions 
Instructions for storing the product When applicable 
Alcohol content When applicable 
Batch number   
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TABLE 3. The requirements for labelling of food supplements according to decree 
834/2014 of Ministry of Agriculture and Forestry 
 
The term “Food Supplement”  
The nature of the effective ingredient In this instance, an herbal extract or 
extracts or the extract drink are suitable 
The amount of daily intake The amount of the effective substance in 
recommended daily intake 
The recommended daily intake The instruction for daily intake, e.g. 10 ml/ 
table spoon 
Indication that the recommended daily 
intake should not be exceeded  
 
Indication that a food supplement should 
not be used to substitute a healthy and 
versatile diet.  
 
Indication that the product should be 
stored out of the reach of small children 
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FIGURE 3. The example of labelling of a food supplement as presented in the food 
supplement guide by Evira (Ravintolisäopas, 20.) 
 
In addition, when the product contains added sugar, Evira suggests including the 
information on the label in the connection of the name of the product. (Ravintolisäopas, 
21.) The Food Act 23/2006 states that all of the information regarding the product shall 
be truthful and appropriate. Giving misleading information is prohibited. As the 
declaration of conformity in appendix 5 states, the health claims are in accordance with 
the EU laws 1924/2006 and 432/2012. The local Austrian authority, AGES, has checked 
the wording and stated it to comply with the mentioned law. The wording should be taken 
into consideration when compiling the translations.  
 
According to the Food Act 23/2006, the marking in the labelling shall be of certain size. 
The obligatory information shall be given so that the type size x-height is at least 1,2 mm. 
In small packages where the largest surface area is less than 80 cm2, the x-height can be 
reduced to 0,9 mm. (Ravintolisäopas, 22.) 
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6 PHARMACEUTICAL PRODUCTS 
 
 
The legislation and demands regarding medical products are vast and detailed. The 
pharmaceutical products of RIVIERA are classified as traditional herbal medicines. 
Hence, this chapter will cover the special requirements for traditional herbal medicines 
instead of the whole vast entity of different medicinal products.  
 
Nonetheless, the general obligations for medicinal products also apply to traditional 
herbal medicines. For example, the good manufacturing procedure for is obligatory for 
medicine producers. The details of the Pharma GMP are detailed in in Commission 
Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC 
respectively. (EudraLex vol. 4 GMP. n.d.) The European Medicines Agency, EMA, is the 
authority who coordinates inspections to ensure the compliance with the GMP. RIVIERA 
follows the guidelines with great precision and has completed the registration and 
authorization processes.  
 
 
6.1 Traditional Herbal Medicines 
 
A traditional herbal medicine is a medicine meant for human use and has either herbal 
substance or herbal preparation or both as active ingredients. The registration for 
traditional herbal medicine requires that the product has been in frequent use as a 
medicine at least for 30 years, from which 15 years in the area of the European Union. 
(2009/773) 
 
The European Community Directive 2001/83/EC on the Community code relating to 
medicinal products for human use gives the general guidelines for the requirements 
concerning medicinal products. It states the information that needs to be provided about 
the products, the contents of a packaging leaflet and authorization and registration of the 
products among many other things. The directive 2004/24/EC amending the 2001/83/EC 
as regarding traditional herbal medicinal products states the definition for traditional 
herbal medicinal product and requirements for registration and authorization. 
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The competent authority in Finland regarding medicinal products is Fimea. The national 
Medicine Act 31.1.2003/80 states the requirements concerning the medicines, 
manufacturing, distribution, the sales permissions and registration. Article 5 states the 
requirements for traditional herbal medicines which are described in more detail in article 
22. The requirements are equivalent to the 2004/24/EC. The sales of a traditional herbal 
medicine require a marketing authorization granted by Fimea. The medicine needs to 
fulfil the requirements stated in European pharmacopeia or other requirements regarding 
manufacturing and quality. (2005/835.) 
 
According to the Medicine Act, all necessary information concerning the medicine as 
well as labelling and packaging need to be translated into both Finnish and Swedish. The 
translations of the package leaflet and a summary of the product characteristics need to 
be provided already in the process of applying the marketing authorization.  
 
There are multiple options for applying for the marketing authorization (Fimea. n.d.). 
RIVIERA has used the MRP, mutual recognition procedure, when entering other markets, 
thus, it would be used in this instance as well. MRP and application for marketing 
authorization are described in 6.3.  
 
The distributor has many responsibilities that are stated in several pieces of legislation. 
He needs to have a permission for wholesales of medicines and cooperate with Fimea 
(2005/835). However, in the beginning it is more important that the products of RIVIERA 
Pharma & Cosmetics are in conformity with the national legislation in order to receive 
the market authorization. 
 
 
6.2 Alcohol content 
 
The Schweden Bitter is registered as a medicine in Austria. The alcohol content of the 
product is 38 vol-%. The act 1088/2010 on prescription of medicine by the Finnish 
Ministry of Social affairs and Health determines that an alcoholic medicine is a medicine 
that contains over 5 m-% of ethanol. Alcoholic medicines are to be prescribed by a 
qualified physician. Even with the medicines that are prescribed by a doctor, the limitation 
for alcohol in medicine that are consumed internally is 20 m-% unless it is proven to 
require higher concentration of alcohol. 
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Therefore, the sales of Schweden Bitter would be highly limited, if even possible. Finland 
is a nation that takes issues related to alcohol rather seriously, doctors are not likely to 
prescribe such products. In conclusion, the sales of the Schweden Bitter in Finland as a 
medicine is not worthwhile. 
 
 
6.3 MRP 
 
The other traditional herbal medicine of RIVIERA Pharma and Cosmetics is the Ribwort 
Plantain Cough Syrup. The market authorization would be applied through the mutual 
recognition process. The process requires that the authorization has been already granted 
for the product in some member state. Fimea grants the market authorization based on the 
permission already granted in a reference member state. (Fimea. n.d.) 
 
The summary of the product characteristics is an agreement between the competent 
authority and the holder of the market authorization. It describes how and for what the 
medicine is used for as well as how the safety and quality of the product have been proved. 
The package leaflet and the labelling need to be translated into both Finnish and Swedish, 
but with the SPC only Finnish is sufficient. However, in MRP the copy of the common 
SPC has to be also provided in English. (Fimea. n.d.) 
 
The SPC has to be provided for Fimea as a word-document. The person applying the 
authorization is required to follow the instructions on formulating the documents and that 
the technical quality is appropriate. Fimea provides templates for the SPC which are to 
be used in the Finnish translation. (Fimea. n.d.) 
 
The labelling and the markings on the packages must include the name of the product, 
concentration, the form of the medicine, active ingredients, quantity, ingredients, 
necessary warnings, the best before –date, instructions for storing, instructions for 
disposal, the owner of the marketing authorization and their address, number of the 
marketing authorization, batch number and the dosage instructions. Traditional herbal 
medicines need to include some special features; the statement that it is a traditional 
herbal medicine and a request to contact a qualified physician if the symptoms are not 
eased and if there are any undesired effects. (Fimea. n.d.) 
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There are also country specific notifications that need to be included in the labelling of 
the product, those are called the Blue Box requirements. They are listed in the website of 
CMDh. Finland has specific requirements that differ a little from the Austrian 
requirements. (Fimea.) The correct wording is presented in the Quality Review 
Documents of the EMA. In addition, the terms used need to be standard terms stated in 
the European pharmacopeia, there are official translation terms. All of the accepted 
standard terms and their translations can be found in the database of EDQM. (Fimea. n.d.) 
 
The article 56a of medicine directive 2004/27/EC requires the packaging to include the 
name of the product in Braille. The information included in the package leaflet should 
also be provided for visually impaired upon request.  
 
The dossier of the application is consisted of a cover letter, an application form and other 
detailed reporting depending on the legal basis stated in the 2001/83/EC articles 8 and 10. 
The handling time for MRP is 90 days and 30 days for control of the translations (Fimea. 
n.d.). The fee for the procedure is 6000 € according to annex I of 210/2016 of the Fimeas 
performances that are subject to charge by the Ministry of Social affairs and Health. 
 
However, as the product was to be granted the marketing authorization, the Ribwort 
Plantain would then probably be added on the Fimea’s list of medicinal herbs, which then 
could have an effect on the food supplement version of the product on the market. Also, 
it is crucial to evaluate whether going through the MRP process will be profitable for the 
company. 
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7 DISCUSSION & CONCLUSION 
 
 
The harmonized legislation in the European Union promotes the export within the 
community. In spite of causing some inconvenience for operators by increasing and 
updating legislation and therefore requirements for different kinds of activities, in the 
whole, the area benefits from the system. If an export process were to be launched, a 
system where all the countries had their own legislation and their own specific 
requirements would make the project much more difficult. Nonetheless, even within the 
current system, there are national requirements. Still, the system eases the process and 
gives a good basis for free movement and open internal market.  
 
 As with any communication between human beings or organizations, the actions are 
based on interpretation of the communication. The regulations set a common framework 
for all the member states. However, the execution of the demands set in those regulations 
depends on the interpretation. Though, the legislation is aimed to be worded so, that there 
are as little as possible room for subjective judgment.  The competent authorities in each 
member state are responsible for the national perception of the EU regulations. That may 
lead to a different kind of focus and emphasis in different member states.  
 
The European Union consists of many different kinds of countries which have different 
kind of culture, climate and needs. The great challenge in the harmonization is to take 
into account the diverse needs of different member states. For example, the recent 
regulations regarding agriculture and forestry have gained a lot of attention lately because 
the guidelines of the EU regulation are not favorable to the Finnish view of how certain 
matters should be dealt with.  
 
The task of building a regulation that can and shall be applicable in all member states is 
not an easy task. The construction of a regulation that includes all possible perspectives 
is close to an impossible mission. Nevertheless, the regulations are built with expert 
groups from different countries and aim for the best objective solution possible. The 
regulations can also be amended when there is not enough information or something 
appears to be less functional as initially thought.  
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In the end, the question comes to the matter of interpretation. When the regulations are 
very precise, not much is left to be interpreted but with some regulations, there is room 
to draw different kinds of conclusions. This work is compiled mostly according to the 
guidelines of Finnish competent authorities as well as some EU regulations. However, 
there is always room for subjective perception and that should be taken into account when 
conducting the procedures described in this work. Still, the work is compiled in great 
precision and meticulousness aiming at an objective and a clear outcome.  
 
 
7.1 Sauna Infusion Oils 
 
Working with chemicals requires an observance to many regulations and directives. 
Those are necessary for building a safe way of handling chemicals. One of the aims of 
the REACH and the CLP are to reduce the use of dangerous chemicals or substitute them 
with less dangerous ones. That is the direction of the development in the field.  
 
Within the EU area the situation is good, because the same requirements are set for 
products that are imported from outside the EU. That has an effect on the mindset of the 
whole world. The EU is a wealthy market. Requiring good quality and safety makes the 
foreign operators improve their operations. The harmonized worldwide standard system 
ISO also supports the development.  
 
 
7.2 Cosmetics 
 
The INCI system is a brilliant way to ease the safe use of cosmetics in the whole EU. The 
nomenclature enables the consumer to recognize the ingredients in spite of the location 
or language in the EU. That helps consumers recognize substances that may be harmful 
to them. For example, some perfuming substances can cause contact allergy.  
 
Nevertheless, the system is not a direct indication of the quality of the product. The 
substances that are present in less than 1 m-% can be stated in any order. That means that 
even if there is a fancy sounding plant oil present and it is the fifth ingredient on the list, 
its proportion can still be far less than 1% of the whole compound. However, some of the 
ingredients have quantity limitations and should only be used in small quantities to 
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provide the desired effect. In conclusion, the INCI is only an indication for the content 
and states the possible allergens.  
 
 
7.3 Medical Devices 
 
The new regulation brings a lot of new requirements but on the other hand also eases the 
process. RIVIERA has an advantage as they can directly develop the products to comply 
with the new regulation. However, the old and the new regulation do not differ 
remarkably, the new one is just much more precise. 
 
The same legislation is applicable to a very vast product range. It includes machines, 
devices and other artifacts such as blood bags and ice gels. The CE-marking that states 
the conformity is also used for example in electrical appliances. This system enables the 
recognition of safe products as well as sets the high-quality requirements. As the quality 
is ever more regulated with the new regulation, the operators and the consumers can trust 
the quality of the products. 
 
 
7.4 Food supplements 
 
There are a lot of legislation regarding foodstuffs. The harmonized system benefits the 
operators and as well as with other products, sets the equal requirements also for products 
imported from outside the EU. The requirements are equal in both Austria and Finland 
and that means that only the translation process is required.  
 
As with the translation, a question of interpretation arises. The Austrian competent 
authority has considered the products to fulfill the requirements of the health claim laws. 
The latest check concerning the accordance of those regulations has been made recently. 
In spite of making a direct translation there can be an issue of what is interpreted as a 
health claim according to the Finnish competent authority. There can be delicate nuances 
in the translations which create different options for perception. If this were to happen, 
the distributor would be notified by Evira and changes to the labels could be made. 
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7.5 Traditional Herbal Medicines  
 
The question whether it is sensible to try to export the pharmaceuticals to Finland is 
significant. The fact that the Schweden Bitter requires a prescription if sold as a medicine 
constricts the possibilities of good sales. Probably a good marketing and positioning the 
product in Alko, if possible, would be more a sensible channel for the sales in Finland, 
even if it was meant to be used as a traditional bitter for stomach. However, that would 
need to be calculated thoroughly as well because the amount of alcohol tax. 
 
Furthermore, the MRP is a big investment for exporting one or two products. If the 
Schweden Bitter was excluded, the only pharmaceutical product would be the Ribwort 
Plantain syrup. There are a few brands on the Finnish market that have a strong position. 
Whether the cough syrup from RIVIERA can challenge those is a question worth 
considering, not to mention the costs of the process.  
 
 
This work compiles the most important regulations and matter needed to consider when 
exporting these product groups to Finland. The model is applicable for all export within 
the EU. As this work summarizes all the necessary steps and laws it helps in the export 
process. The tables presented in appendices 1 and 2 are provided for the company as MS 
Excel sheets to be modified further and possibly used in other processes.  
 
38 
 
SOURCES 
Alkoholilaki 8.12.1994/1143.  
 
Blue Box requirements. 2017. CMDh. Accessed 10.12.2017. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidanc
e/Application_for_MA/CMDh_258_2012_clean.pdf  
 
Bureau Veritas Group. n.d. ISO 22716 – Cosmetics Good Manufacturing Practices. 
Accessed 05.12.2017 http://www.bureauveritas.com/services+sheet/iso-22716-
cosmetics-good-manufacturing-practices_14386 
 
Commission Regulation (EU) No 432/2012 establishing a list of permitted health claims 
made on foods, other than those referring to the reduction of disease risk and to 
chlidren’s development and health. Official Journal of the European Union 16.05.2012.  
 
Cosmetic Product Notification Portal. European Commission, updated 12.12.2017 
Accessed 05.12.2017 https://ec.europa.eu/growth/sectors/cosmetics/cpnp_fi  
 
Council Directive 93/42/EEC concerning medical devices. Official Journal of the 
European Communities. 14.07.1993.  
 
Directive 2001/83/EC of the European Parliament and of the Council on the 
Community code relating to medicinal products for human use. Official Journal of the 
European Communities 06.11.2017.  
 
Directive 2002/46/EC of the European parliament and of the Council on the 
approximation of the laws of the Member States relating to food supplements. Official 
Journal of the European Communities 10.07.2002. Accessed 08.12.2017.  
 
Directive 2004/24/EC of the European Parliament and of the Council amending, as 
regards traditional herbal medicinal products, Directive 2001/83/EC on the Community 
code relating to medicinal products for human use. Official Journal of the European 
Union 31.03.2004.  
 
Directive 2004/27/EC of the European Parliament and of the Council amending 
Directive 2001/83/EC on the Community code relating to medicinal products for human 
use. Official Journal of European Union 31.03.2004.  
 
Directive 2008/68/EC of the European Parliament and of the Council on the inland 
transport of dangerous goods. Official Journal of European Union 24.09.2008.  
 
Dr. Robert Heinz & Partner GmbH & CW. 2016. Research & Management GmbH: 
Medical Consulting. Presentation. Material owned by RIVIERA Pharma & Cosmetics 
GmbH 
 
ECHA. n.d. REACH-asetus tutuksi. Accessed 12.09.2017. 
https://echa.europa.eu/fi/regulations/reach/understanding-reach 
 
Elintarvikelaki 13.1.2006.  
 
39 
 
EN-ISO 11683. 1997. Packaging. Tactile warnings of danger. Requirements. Accessed 
05.12.2017 Requires a right to read. 
 
EudraLex Volume 4 – Good Manufacturing Practice (GMP) guidelines. n.d. European 
Commission. Accessed 10.12.2017. https://ec.europa.eu/health/documents/eudralex/vol-
4_en  
 
European Commission. n.d. Harmonized Standards: Medical Devices. Accessed 
06.12.2017 https://ec.europa.eu/growth/single-market/european-standards/harmonised-
standards/medical-devices_en 
 
Evira. 2017. Eläimistä saatvat ja yhdistelmäelintarvikkeet. Updated 21.09.2017. 
Accessed 11.12.2017. https://www.evira.fi/elintarvikkeet/tuonti-ja-vienti/eun-
jasenmaat-norja-ja-sveitsi/ensisaapumisvalvonta/yhdistelma--ja-elaimista-saatavat-
elintarvikkeet/  
 
Fimea. n.d. Mallitekstit. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/tuoteinformaatio/mallitekstit  
 
Fimea. n.d. Myyntilupahakemus. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/myyntilupahakemus  
 
Fimea. n.d. Myyntiluvat. Accessed 10.12.2017. http://www.fimea.fi/myyntiluvat 
 
Fimea. n.d. Myyntipäällysmerkinnät. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/tuoteinformaatio/myyntipaallysmerkinnat  
 
Fimea. n.d. Perinteisen kasvirohdosvalmisteen rekisteröintihakemuksen vaatimuksista. 
Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/kasvirohdoslaakkeet_ja_homeopaattiset_valmisteet/pe
rinteiset_kasvirohdosvalmisteet/perinteisen_kasvirohdosvalmisteen_rekisterointihakem
uksen_vaatimuksista  
 
Fimea. n.d. Perinteiset kasvirohdosvalmisteet. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/kasvirohdoslaakkeet_ja_homeopaattiset_valmisteet/pe
rinteiset_kasvirohdosvalmisteet  
 
Fimea. n.d. Pistekirjoitus ja pakkausselosteet näkövammaisille. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/tuoteinformaatio/pistekirjoitus_ja_pakkausselosteet_na
kovammaisille  
 
Fimea. n.d. Valmisteyhteenveto. Accessed 10.12.2017. 
http://www.fimea.fi/myyntiluvat/tuoteinformaatio/valmisteyhteenveto  
 
Good Manufacturing Practice. n.d. European Medicines Agency EMA. Accessed 
10.12.2017. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_conten
t_001205.jsp&mid=WC0b01ac0580027088  
 
Kemikaalilaki 599/2013.  
 
Kielilaki 6.6.2003/423.  
40 
 
 
Komptmann, S. 2014 Roles Under REACH (part 1). CHEManager International 
25.11.2014. http://www.chemanager-online.com/en/topics/chemicals-distribution/roles-
under-reach-part-1 
 
Laki alkoholi- ja alkoholijuomaverosta 29.12.1994/1471.  
 
Laki kosmeettisista valmisteista 492/2013.  
 
Laki terveydenhuollon laitteista ja tarvikkeista 692/2010.  
 
Laki vaarallisten aineiden kuljetuksesta 2.8.1994/719.  
 
Lääkelaki 10.4.1987/395. (2003/80; 2005/835; 2009/773) 
 
Maa- ja metsätalousministeriön asetus elintarviketietojen antamisesta kuluttajille 
834/2014.  
 
Maa- ja metsätalousministeriön asetus ravintolisistä 78/2010.  
 
Product Information Templates. n.d. European Medicines Agency. Accessed 
10.12.2017. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/docu
ment_listing_000134.jsp&mid=WC0b01ac0580022c59  
 
Ravintolisäopas elintarvikevalvojille ja elintarviealan toimijoille. 2016. Evira. PDF. 
Accessed 08.12.2017. https://www.evira.fi/globalassets/tietoa-
evirasta/julkaisut/oppaat/ravintolisaopas.pdf  
 
Regulation (EC) No 853/2004 Of the European Parliament and of the Council laying 
down specific hygiene rules for on the hygiene of foodstuffs. Official Journal of 
European Union 29.04.2004.  
 
Regulation (EC) No 1223/2009 of the European Parliament and of the Council on 
cosmetic products. Official Journal of European Union 30.11.2009.  
 
Regulation (EC) No 1272/2008 of the European Parliament and of the Council on 
classification, labelling and packaging of substances and mixtures. Official Journal of 
European Union 16.12.2008.  
 
Regulation (EC) No 1907/2006 of the European Parliament and of the Council 
concerning the Registration, Evaluation, Authorization and Restriction of Chemicals 
(REACH). Official Journal of European Union 18.12.2006.  
 
Regulation (EC) No 1924/2006 of the European Parliament and of the Council on 
nutrition and health claims made on foods. Official Journal of European Union. 
20.12.2006.  
 
Regulation (EU) 2017/745 of the European Parliament and of the Council on medical 
devices. Official Journal of the European Union 05.04.2017.  
 
RIVIERA Pharma & Cosmetics Webpage, 2014. Accessed 22.08.2017 http://riviera.at/ 
41 
 
 
Salminen, L. 2013. EU ja CE-merkki. 19.03.2013. Kuopio/Turku: Medifiles 
presentation. Accessed 06.12.2017. 
https://www2.uef.fi/documents/976466/1745345/06-19Salminen+EU+CE/945a3d50-
9925-4aac-977a-8546cdb44450  
 
Scholtz, S., Menzl, S., Rupparath, C., Becker, M. and Auffarth, G. The CE Mark: A 
Medical Device’s Passport to A Multibillion Euro Market. The Ophthalmologist. 
Accessed 07.2017. https://theophthalmologist.com/issues/a-fantastic-voyage-into-your-
patients-eyes/the-ce-mark-a-medical-devices-passport-to-a-multibillion-euro-market/  
 
Sosiaali- ja terveysministeriön asetus kemikaalien määrätietojen toimittamisesta 
1155/2011.  
 
Sosiaali- ja terveysministeriön asetus lääkkeen määräämisestä 1088/2010.  
 
Suomen säädöskokoelma 23.3.2016 201/2016. Lääkealan turvallisuus- ja 
kehittämiskeskuksen päätös lääkeluettelosta.  
 
Teknokemian Yhdistys ry. n.d. Kosmetiikan ainesosaluettelo – mitä se kertoo 
tuotteesta? Accessed 05.12.2017 
http://www.teknokemia.fi/fin/kosmetiikka/kosmetiikan_puheenaiheita/inci-
lista_kuinka_sita_luetaan/ 
 
Trade Helpdesk. 2017. European Commission. Accessed 22.08.2017 
http://exporthelp.europa.eu/thdapp/display.htm?page=rt/rt_ValueAddedTax.html&docT
ype=main&languageId=EN 
 
 
Trafi. 2017. Vaarallisten aineiden tiekuljetukset, updated 07.04.2017. Accessed 
04.12.2017 
https://www.trafi.fi/liikennejarjestelma/vaaralliset_aineet/vak_tiekuljetukset  
 
Tukes. 2016.  REACH-asetus, updated 11.05.2016.  Accessed 12.09.2017.  
http://www.tukes.fi/fi/Toimialat/Kemikaalit-biosidit-ja-kasvinsuojeluaineet/Teollisuus--
ja-kuluttajakemikaalit/REACH---asetus/ 
 
Tukes. 2017. Kemikaalitietojen ilmoittaminen, updated 17.03.2017 
http://www.tukes.fi/fi/Toimialat/Kemikaalit-biosidit-ja-
kasvinsuojeluaineet/Kemikaalitietojen-ilmoittaminen/ 
 
Tukes. 2017. Luokitus, merkinnät ja pakkaaminen, updated 04.05.2017.  Accessed 
12.09.2017 http://www.tukes.fi/fi/Toimialat/Kemikaalit-biosidit-ja-
kasvinsuojeluaineet/Luokituspakkaaminen-ja-merkinnat/ 
 
Tukes. 2017. Vaarallisten aineiden kuljetus, updated 28.08.2017 Accessed 12.09.2017 
http://www.tukes.fi/fi/Toimialat/Kemikaalit-ja-kaasu/Vaarallisten-aineiden-kuljetus/  
 
Valtioneuvoston asetus vaarallisten aineiden kuljetuksesta tiellä 194/2002.  
 
Valvira, 2010. Määräys: Terveydenhuollon laitteesta ja tarvikkeesta tehtävät 
laiterekisteri-ilmoitukset. Accessed 06.12.2017. 
42 
 
http://www.valvira.fi/documents/14444/37132/maarays_2_2010_laiterekisteri_ilmoitus.
pdf 
 
Valvira, 2017. Lääkinnällisiä laitteita koskevat EU-asetukset voimaan tänään. Accessed 
06.12.2017. http://www.valvira.fi/-/laakinnallisia-laitteita-koskevat-eu-asetukset-
voimaan-tanaan 
 
Verordnung des Bundesministers für wirtschaftliche Angelegenheiten betreffend 
Fertigpackungen (Fertigpackungsverordnung - FPVO 1993) 
 
Vientiprosessiopas. 2013. Tarjouspyynnöstä tavarantoimituksiin, 16.10.2013. Accessed 
23.08.2017 
http://www.exportfinland.fi/documents/10304/216253/Vientiprosessiopas.pdf 
 
Your Europe. 2017. Selling within the EU. 06.12.2017. Accessed 22.08.2017 
http://europa.eu/youreurope/business/sell-abroad/import-export/index_en.htm 
 
Yrittäjät, Vaasa: Vienti. n.d. Accessed 23.08.2017 https://www.yrittajat.fi/rannikko-
pohjanmaan-yrittajat/vaasan-yrittajat-vasa-foretagare/a/vaasan-yrittajat-vasa-
foretagare/kansainvalistyminen/vienti 
 
 
 
 
 
 
43 
 
APPENDICES 
Appendix 1. Export nach Finnland: Verantwortlichkeit 
 
 
EX
P
O
R
T	
N
A
C
H
	F
IN
N
LA
N
D
:	V
ER
A
N
TW
O
R
TL
IC
H
K
LE
IT
P
ro
d
u
kt
gr
u
p
p
e
R
IV
IE
R
A
	P
h
ar
m
a	
C
o
sm
et
ic
s	
G
m
b
H
Im
p
o
rt
eu
r	
in
	F
in
n
la
n
d
Fi
n
n
is
ch
e	
B
e
h
ö
rd
e
V
e
rw
an
d
te
	G
e
se
tz
ge
b
u
n
g	
(m
it
	
A
u
sn
ah
m
e
	d
e
r	
n
at
io
n
al
en
	
ö
st
er
re
ic
h
is
ch
en
	G
e
se
tz
e
)
K
o
sm
e
ti
ka
Ü
b
er
se
tz
e
n
	d
e
r	
P
ro
d
u
kt
in
fo
rm
at
io
n
e
n
	(
N
am
e
,	
V
er
w
e
n
d
u
n
g	
u
n
d
	m
ö
gl
ic
h
e
	V
o
rs
ic
h
ts
m
aß
n
ah
m
e
n
)
Ü
b
er
p
rü
fu
n
g	
d
er
	Ü
b
er
se
tz
u
n
ge
n
	u
n
d
	d
as
s	
si
e	
m
it
	d
em
	
G
es
et
z	
st
im
m
t,
	C
P
N
P
-B
en
ac
h
ri
ch
ti
gu
n
g,
	Ü
b
e
rp
rü
fu
n
g,
	
d
as
s	
d
ie
	A
b
la
u
fd
at
en
	g
ü
lt
ig
	s
in
d
Tu
ke
s,
	d
er
	Z
o
ll	
K
o
sm
et
ik
re
ch
t	
1
2
2
3
/2
0
0
9
,	
K
o
sm
et
iik
ka
la
ki
	4
9
2
/2
0
1
3
N
ah
ru
n
gs
er
gä
n
tz
u
n
g	
St
el
le
n
	S
ie
	E
ti
ke
tt
en
	b
e
re
it
,	d
ie
	g
em
äß
	d
e
n
	T
ab
e
lle
n
	
2
	u
n
d
	3
	u
n
d
	A
b
b
ild
u
n
g	
3
	v
o
rb
e
re
it
e
t	
w
u
rd
en
.	B
it
te
	
b
ea
ch
te
n
	S
ie
	d
ie
	G
rö
ß
e
	d
e
s	
Ty
p
s	
b
ei
	d
er
	
V
o
rb
er
ei
tu
n
g	
d
er
	E
ti
ke
tt
en
.	G
e
b
en
	S
ie
	z
u
sä
tz
lic
h
e	
In
fo
rm
at
io
n
en
	a
u
f	
A
n
fr
ag
e	
an
.
Ei
n
e	
M
el
d
u
n
g	
an
	E
vi
ra
	v
o
r	
d
em
	In
ve
rk
eh
rb
ri
n
ge
n
	d
er
	
P
ro
d
u
kt
e
,	w
ie
	b
ei
m
	K
e
n
n
ze
ic
h
n
u
n
gs
m
o
d
e
ll	
u
n
d
	
m
ö
gl
ic
h
en
	A
n
la
ge
n
	(
K
o
n
fo
rm
it
ät
se
rk
lä
ru
n
g)
,	p
as
se
n
d
e	
R
äu
m
e
n
,	d
ie
	a
ls
	"
Le
b
en
sm
it
te
lb
et
ri
eb
"	
kl
as
si
fi
zi
e
rt
	s
in
d
	
h
ab
en
.
Ev
ir
a,
	V
al
vi
ra
1
7
8
/2
0
0
2
	ü
b
er
	d
ie
	S
ic
h
er
h
ei
t	
vo
n
	
Le
b
e
n
sm
it
te
ln
,	F
in
n
is
ch
	
Le
b
e
n
sm
it
te
lv
er
o
rd
n
u
n
g	
2
3
/2
0
0
6
,	
M
in
is
te
ri
u
m
	f
ü
r	
La
n
d
-	
u
n
d
	
Fo
rs
tw
ir
ts
ch
af
t	
V
er
o
rd
n
u
n
g	
7
8
/2
0
1
0
	
ü
b
e
r	
N
ah
ru
n
se
rg
än
zu
n
gs
m
it
te
ln
,	
1
1
4
3
/1
9
9
4
	A
lc
o
h
o
ls
te
u
er
re
ch
t,
		
G
e
su
n
d
h
ei
ts
b
e
zo
ge
n
e	
V
er
o
rd
n
u
n
g	
1
9
2
4
/2
0
0
6
G
ef
ah
rg
u
t
Ü
b
er
se
tz
e
n
	u
n
d
	B
e
re
it
st
el
le
n
	d
er
	E
ti
ke
tt
e
n
	m
it
	d
e
n
	
Si
gn
al
w
ö
rt
e
rn
,	P
ik
to
gr
am
m
en
,	G
ef
ah
re
n
h
in
w
ei
se
n
	
u
n
d
	S
ic
h
er
h
ei
ts
h
in
w
e
is
e
	u
n
d
	d
en
	A
n
w
ei
su
n
ge
n
	a
u
f	
Fi
n
n
is
ch
	u
n
d
	S
ch
w
ed
is
ch
.	Ü
b
er
se
tz
u
n
g	
d
er
	
Si
ch
er
h
ei
ts
d
at
e
n
b
lä
tt
e
r	
au
f	
Fi
n
n
is
ch
,	S
ch
w
ed
is
ch
	
o
d
e
r	
b
ei
d
e
s.
	D
ie
	S
ic
h
e
rh
e
it
sd
at
en
b
lä
tt
er
	m
ü
ss
en
	
sp
ät
es
te
n
s	
b
e
i	d
er
	L
ie
fe
ru
n
g	
d
er
	P
ro
d
u
kt
e
	z
u
r	
V
er
fü
gu
n
g	
ge
st
el
lt
	w
e
rd
e
n
.	B
er
ei
ts
te
llu
n
g	
vo
n
	
In
fo
rm
at
io
n
en
	im
	F
al
le
	v
o
n
	Ä
n
d
er
u
n
ge
n
	a
m
	P
ro
d
u
kt
	
o
d
e
r	
d
er
	K
en
n
ze
ic
h
n
u
n
g.
B
en
ac
h
ri
ch
ti
gu
n
g	
vo
n
	T
u
ke
s	
ü
b
e
r	
d
ie
	P
ro
d
u
kt
e	
(K
e
m
ik
aa
li-
ilm
o
it
u
s,
	T
u
ke
s)
.	A
u
f	
d
ie
	r
ic
h
ti
ge
	L
ag
e
ru
n
g	
ac
h
te
n
.	H
al
te
n
	d
ie
	S
ic
h
e
rh
e
it
si
n
fo
rm
at
io
n
e
n
	d
e
r	
P
ro
d
u
kt
e
.	B
er
ei
ts
te
llu
n
g	
zu
sä
tz
lic
h
er
	In
fo
rm
at
io
n
e
n
	a
u
f	
A
n
fr
ag
e
.
Tu
ke
s,
	d
er
	Z
o
ll	
R
EA
C
H
	1
9
0
7
/2
0
0
6
,	C
LP
	1
2
7
2
/2
0
0
8
,	
K
em
ik
aa
lil
ak
i	5
9
9
/2
0
1
3
,	n
at
io
n
al
e
s	
G
e
se
tz
	ü
b
er
	d
ie
	N
o
ti
fi
zi
e
ru
n
g	
1
1
5
5
/2
0
1
1
M
e
d
iz
in
is
ch
es
	G
er
ät
e
/	
M
ed
iz
in
p
ro
d
u
kt
e
C
E-
K
en
n
ze
ic
h
n
u
n
g,
	K
o
n
fo
rm
it
ät
se
rk
lä
ru
n
g;
	
Ü
b
er
se
tz
u
n
ge
n
	v
o
n
	2
0
1
7
/7
4
5
	A
rt
ik
el
	1
0
	(
1
1
)	
u
n
d
	
K
o
n
fo
rm
it
ät
se
rk
lä
ru
n
g	
u
n
d
	z
u
sä
tz
lic
h
e	
In
fo
rm
at
io
n
en
.	A
n
w
ei
su
n
ge
n
	z
u
	L
ag
er
u
n
g	
u
n
d
	
Tr
an
sp
o
rt
.	F
ü
h
re
n
	S
ie
	A
u
fz
ei
ch
n
u
n
ge
n
	ü
b
er
	
B
es
ch
w
er
d
en
	u
n
d
	m
ö
gl
ic
h
e
	R
is
ik
en
.
Zu
sa
m
m
en
ar
b
e
it
	m
it
	d
e
m
	H
er
st
e
lle
r,
	S
ic
h
e
rs
te
llu
n
g,
	
d
as
s	
d
ie
	g
en
an
n
te
n
	Ü
b
e
rs
e
tz
u
n
ge
n
	k
o
rr
ek
t	
si
n
d
	u
n
d
	
d
e
r	
In
h
al
t	
d
er
	K
o
n
fo
rm
it
ät
se
rk
lä
ru
n
g	
u
n
d
	d
e
r	
C
E-
K
en
n
ze
ic
h
n
u
n
g	
an
ge
m
es
se
n
	s
in
d
;	K
o
n
ta
kt
au
fn
ah
m
e
	
m
it
	d
e
m
	H
er
st
e
lle
r	
w
eg
en
	P
ro
b
le
m
en
	o
d
er
	
B
es
ch
w
er
d
en
.	B
e
re
it
st
el
lu
n
g	
vo
n
	In
fo
rm
at
io
n
en
	f
ü
r	
d
ie
	
zu
st
än
d
ig
e	
B
eh
ö
rd
e	
au
f	
A
n
fr
ag
e.
V
al
vi
ra
EU
-R
ic
h
tl
in
ie
	f
ü
r	
M
ed
iz
in
p
ro
d
u
kt
e	
9
3
/4
2
/E
EC
,	V
er
o
rd
n
u
n
g	
2
0
1
7
/7
4
5
	
ü
b
e
r	
M
e
d
iz
in
p
ro
d
u
kt
e,
	F
in
n
is
ch
	
G
e
se
tz
	ü
b
er
	M
e
d
iz
in
p
ro
d
u
kt
e	
6
2
9
/2
0
1
0
,	F
in
n
is
ch
e	
Sp
ra
ch
e
ve
ro
rd
n
u
n
g	
2
0
0
3
/4
2
3
A
rz
n
ei
m
it
te
ln
D
ie
	e
rf
o
rd
er
lic
h
en
	D
at
en
	f
ü
r	
d
ie
	M
ar
kt
zu
la
ss
u
n
g,
	
P
ak
e
ti
n
fo
rm
at
io
n
en
,	B
e
ip
ac
kz
e
tt
el
	u
n
d
	
Et
ik
et
te
n
/L
ab
le
s	
m
ü
ss
e
n
	in
	F
in
n
is
ch
	u
n
d
	S
ch
w
ed
is
ch
	
ü
b
er
se
tz
t	
w
e
rd
e
n
,	S
P
C
	in
	F
in
n
is
ch
	u
n
d
	E
n
gl
is
ch
,	d
ie
	
B
lu
e-
B
o
x-
A
n
fo
rd
e
ru
n
ge
n
	b
e
rü
ck
si
ch
ti
ge
n
,	d
ie
	
G
eb
ü
h
r	
d
e
r	
M
R
P
	b
e
za
h
le
n
Si
ch
er
st
el
lu
n
g,
	d
as
s	
al
le
	f
ü
r	
d
en
	V
e
rt
ri
eb
	v
o
n
	
A
rz
n
ei
m
it
te
ln
	e
rf
o
rd
er
lic
h
e
n
	R
ec
h
ts
vo
rs
ch
ri
ft
e
n
	
e
in
ge
h
al
te
n
	w
e
rd
e
n
,	Z
u
sa
m
m
en
ar
b
e
it
	m
it
	F
im
e
a.
Fi
m
ea
9
1
/3
5
6
/E
EC
-2
0
0
3
/9
4
/E
C
-
9
1
/4
1
2
/E
EC
,	F
in
n
is
ch
	
A
rz
n
ei
m
it
te
lv
er
o
rd
n
u
n
g	
3
9
5
/1
9
8
7
	in
	
d
er
	g
e
än
d
e
rt
en
	F
as
su
n
g,
	
2
0
0
4
/8
3
/E
C
,		
Fi
n
n
is
ch
e
	R
ez
e
p
tu
r	
vo
n
	A
ZM
	1
0
8
8
/2
0
1
0
,	B
ra
ill
e	
2
0
0
4
/2
7
/E
C
,	M
R
P
	G
eb
ü
h
r	
2
1
0
/2
0
1
6
	
A
n
b
au
	I
44 
 
Appendix 2. Export to Finland: Responsibilities 
 
EX
P
O
R
T	
TO
	F
IN
LA
N
D
:	R
ES
P
O
N
SI
B
IL
IT
IE
S
P
ro
d
u
ct
	G
ro
u
p
R
IV
IE
R
A
	P
h
ar
m
a	
C
o
sm
et
ic
s	
G
m
b
H
Im
p
o
rt
e
r	
in
	F
in
la
n
d
Fi
n
n
is
h
	A
u
th
o
ri
ty
R
e
la
te
d
	le
gi
sl
at
io
n
	(
e
xc
lu
d
in
g	
n
at
io
n
al
	A
u
st
ri
an
	la
w
s)
C
o
sm
e
ti
cs
tr
an
sl
at
in
g	
th
e
	p
ro
d
u
ct
	in
fo
rm
at
io
n
	(
n
am
e
,	u
se
	a
n
d
	p
o
ss
ib
le
	
ca
u
ti
o
n
s)
ch
e
ck
in
g	
th
e	
tr
an
sl
at
io
n
s	
an
d
	t
h
ei
r	
ac
co
rd
an
ce
	t
o
	t
h
e	
la
w
,	C
P
N
P
	n
o
ti
fi
ca
ti
o
n
,	c
h
ec
ki
n
g	
th
at
	t
h
e	
e
xp
ir
at
io
n
	
d
at
e
s	
ar
e	
va
lid
Tu
ke
s,
	C
u
st
o
m
s	
C
o
sm
et
ic
	la
w
	1
2
2
3
/2
0
0
9
,	
K
o
sm
e
ti
ik
ka
la
ki
	4
9
2
/2
0
1
3
Fo
o
d
	s
u
p
p
le
m
e
n
ts
P
ro
vi
d
e	
la
b
el
s	
p
re
p
ar
e
d
	a
cc
o
rd
in
g	
to
	t
ab
le
s	
2
	a
n
d
	3
	a
n
d
	f
ig
u
re
	
3
.	P
le
as
e	
n
o
te
	t
h
e	
si
ze
	o
f	
ty
p
e
	w
h
en
	p
re
p
ar
in
g	
th
e	
la
b
e
ls
.	
P
ro
vi
d
e	
ad
d
it
io
n
al
	in
fo
rm
at
io
n
	u
p
o
n
	r
e
q
u
es
t.
A
	n
o
ti
fi
ca
ti
o
n
		t
o
	E
vi
ra
	b
e
fo
re
	p
la
ci
n
g	
th
e
	p
ro
d
u
ct
s	
o
n
	
th
e	
m
ar
ke
t,
	a
s	
w
it
h
	t
h
e
	m
o
d
e
l	o
f	
la
b
el
lin
g	
&
	p
o
ss
ib
le
	
at
ta
ch
m
e
n
ts
	(
d
e
cl
ar
at
io
n
	o
f	
co
n
fo
rm
it
y)
	H
av
in
g	
sp
ac
es
	
th
at
	a
re
	c
la
ss
if
ie
d
	a
s	
a	
"f
o
o
d
	e
st
ab
lis
h
m
en
t"
.
Ev
ir
a,
	V
al
vi
ra
1
7
8
/2
0
0
2
	o
n
	s
af
e
ty
	o
f	
fo
o
d
st
u
ff
s,
	
Fi
n
n
is
h
	F
o
o
d
	A
ct
	2
3
/2
0
0
6
,	
M
in
is
tr
y	
o
f	
A
gr
ic
u
lt
u
re
	a
n
d
	
Fo
re
st
ry
	r
eg
u
la
ti
o
n
	7
8
/2
0
1
0
	o
n
	
fo
o
d
	s
u
p
p
le
m
en
ts
,	1
1
4
3
/1
9
9
4
	
al
co
h
o
l	t
ax
	la
w
,		
h
ea
lt
h
	c
la
im
	
re
gu
la
ti
o
n
	1
9
2
4
/2
0
0
6
D
an
ge
ro
u
s	
G
o
o
d
s
Tr
an
sl
at
in
g	
an
d
	p
ro
vi
d
in
g	
th
e	
la
b
e
ls
	w
it
h
	t
h
e
	s
ig
n
al
	w
o
rd
s,
	
p
ic
to
gr
am
s,
	h
az
ar
d
	s
ta
te
m
en
ts
	a
n
d
	p
re
ca
u
ti
o
n
ar
y	
st
at
em
en
ts
	
as
	w
el
l	a
s	
th
e
	in
st
u
ct
io
n
s	
in
	F
in
n
is
h
	a
n
d
	S
w
ed
is
h
.	T
ra
n
sl
at
in
g	
th
e
	s
af
et
y	
d
at
a	
sh
e
et
s	
to
	F
in
n
is
h
,	S
w
ed
is
h
	o
r	
b
o
th
.	T
h
e
	s
af
et
y	
d
at
a	
sh
e
et
s	
n
e
ed
	t
o
	b
e
	p
ro
vi
d
ed
	a
t	
th
e
	la
te
st
	w
h
e
n
	t
h
e	
p
ro
d
u
ct
s	
ar
e	
d
el
iv
er
ed
.	P
ro
vi
d
in
g	
in
fo
rm
at
io
n
	in
	c
as
e
	o
f	
ch
an
ge
s	
in
	t
h
e
	p
ro
d
u
ct
	o
r	
la
b
e
lli
n
g.
M
ak
in
g	
a	
n
o
ti
fi
ca
ti
o
n
	t
o
	T
u
ke
s	
ab
o
u
t	
th
e	
p
ro
d
u
ct
s	
(K
em
ik
aa
li-
ilm
o
it
u
s,
	T
u
ke
s)
.	T
ak
in
g	
ca
re
	o
f	
th
e	
ap
p
ro
p
ri
at
e	
st
o
ra
gi
n
g.
	H
o
ld
in
g	
o
n
to
	t
h
e	
sa
fe
ty
	
in
fo
rm
at
io
n
	o
f	
th
e	
p
ro
d
u
ct
s.
	P
ro
vi
d
in
g	
ad
d
it
io
n
al
	
in
fo
rm
at
io
n
	u
p
o
n
	r
eq
u
e
st
.
Tu
ke
s,
	C
u
st
o
m
s	
R
EA
C
H
	1
9
0
7
/2
0
0
6
,	C
LP
	
1
2
7
2
/2
0
0
8
,	K
e
m
ik
aa
lil
ak
i	
5
9
9
/2
0
1
3
,	N
at
io
n
al
	la
w
	a
b
o
u
t	
n
o
ti
fi
ca
ti
o
n
	1
1
5
5
/2
0
1
1
M
e
d
ic
al
	D
ev
ic
es
C
E-
	m
ar
ki
n
g,
	d
e
cl
ar
at
io
n
	o
f	
co
n
fo
rm
it
y;
	t
ra
n
sl
at
io
n
s	
o
f	
2
0
1
7
/7
4
5
	a
rt
ic
le
	1
0
	(
1
1
)	
as
	w
e
ll	
as
	d
e
cl
ar
at
io
n
	o
f	
co
n
fo
rm
it
y	
an
d
	a
d
d
it
io
n
al
	in
fo
rm
at
io
n
.	I
n
st
ru
ct
io
n
s	
o
n
	s
to
ra
ge
	a
n
d
	
tr
an
sp
o
rt
at
io
n
.	K
e
ep
	r
e
co
rd
	o
n
	c
o
m
p
la
in
ts
	a
n
d
	p
o
ss
ib
le
	r
is
ks
.
C
o
-o
p
e
ra
ti
o
n
	w
it
h
	m
an
u
fa
ct
u
re
r,
	e
n
su
ri
n
g	
th
at
	t
h
e	
m
e
n
ti
o
n
e
d
	t
ra
n
sl
at
io
n
s	
ar
e	
co
rr
e
ct
	a
n
d
	t
h
e	
co
n
te
ct
	o
f	
d
e
cl
ar
at
io
n
	o
f	
co
n
fo
rm
it
y	
an
d
	t
h
e	
C
E	
m
ar
ki
n
g	
ar
e
	
ap
p
ro
p
ri
at
e;
	c
o
n
ta
ct
in
g	
m
an
u
fa
ct
u
re
r	
re
ga
rd
in
g	
an
y	
p
ro
b
le
m
s	
o
r	
co
m
p
la
in
ts
.	P
ro
vi
d
in
g	
in
fo
rm
at
io
n
	t
o
	
co
m
p
e
te
n
t	
au
th
o
ri
ty
	u
p
o
n
	r
eq
u
e
st
.
V
al
vi
ra
EU
	d
ir
ec
ti
ve
	o
f	
m
ed
ic
al
	d
ev
ic
e
s	
9
3
/4
2
/E
EC
,	R
eg
u
la
ti
o
n
	2
0
1
7
/7
4
5
	
o
f	
m
e
d
ic
al
	d
e
vi
ce
s,
	L
ak
i	
te
rv
e
yd
e
n
h
u
o
llo
n
	la
it
te
is
ta
	
6
2
9
/2
0
1
0
,	K
ie
lil
ak
i	2
0
0
3
/4
2
3
M
ed
ic
in
e
P
ro
vi
d
in
g	
n
ec
es
sa
ry
	d
at
a	
fo
r	
th
e
	m
ar
ke
t	
au
th
o
ri
za
ti
o
n
,	p
ac
ka
ge
	
in
fo
rm
at
io
n
,	l
e
af
le
t	
an
d
	la
b
e
lli
n
g	
n
ee
d
	t
o
	b
e	
tr
an
sl
at
e
d
	t
o
	
Fi
n
n
is
h
	a
n
d
	S
w
e
d
is
h
,	S
P
C
	in
	F
in
n
is
h
	a
n
d
	E
n
gl
is
h
,	t
ak
e	
in
to
	
ac
co
u
n
t	
th
e
	b
lu
e	
b
o
x	
re
q
u
ir
e
m
e
n
ts
,	p
ay
	t
h
e	
fe
e	
o
f	
M
R
P
En
su
ri
n
g	
th
at
	a
ll	
le
gi
sl
at
io
n
	r
eq
u
ir
e
d
	f
o
r	
d
is
tr
ib
u
ti
o
n
	o
f	
m
e
d
ic
in
e
s	
is
	f
o
llo
w
ed
,	c
o
o
p
e
ra
ti
o
n
	w
it
h
	F
im
ea
.
Fi
m
e
a
9
1
/3
5
6
/E
EC
-2
0
0
3
/9
4
/E
C
-
9
1
/4
1
2
/E
EC
,	F
in
n
is
h
	M
ed
ic
in
e
	
A
ct
	3
9
5
/1
9
8
7
	a
s	
am
e
n
d
ed
,	
2
0
0
4
/8
3
/E
C
,		
P
re
sr
ip
ti
o
n
	o
f	
m
e
d
ic
in
e
s	
1
0
8
8
/2
0
1
0
,	B
ra
ill
e
	
2
0
0
4
/2
7
/E
C
,	M
R
P
	f
e
e	
2
1
0
/2
0
1
6
	
an
n
ex
	I
45 
 
Appendix 3. Statement CLP Kennzeichnung (RIVIERA Pharma & Cosmetics GmbH 
2017) 
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Appendix 4. STATEMENT: Compliance with EU Regulation: Cosmetics (RIVIERA 
Pharma & Cosmetics GmbH 2017) 
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Appendix 5. Declaration of Conformity: Food Supplements (RIVIERA Pharma & 
Cosmetics GmbH) 
 
